Merck's Durham N.C. site gets FDA approval to manufacture bulk varicella

Merck (MRK) says its Durham site has received FDA clearance to manufacture bulk varicella at its site in Durham, North Carolina.

The approval enables the site to produce bulk varicella which is used in MRK's vaccines to protect against chickenpox and shingles.

In 2010, the site was approved to produce finished chickenpox vaccines.

Over the longer term, the company plans for the site to produce bulk and finished product for other Merck childhood vaccines, and for the shingles vaccines as well.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs